Table 3.
Outcome of Patients in CGCR by Increases in QPCR
| QPCR Log Increase | No. of Patients | Imatinib Dose Escalation | CML Progression | Follow-Up From QPCR Increase (months) |
|
|---|---|---|---|---|---|
| Median | Range | ||||
| Persistent MMR | |||||
| Any | 28 | 0 | 0 | 36 | 3-62 |
| Loss of MMR | |||||
| > 0.5-1 | 12 | 0 | 0 | 34 | 14-59 |
| > 1-2 | 25 | 0 | 2 | 31 | 6-52 |
| > 2 | 11 | 4 | 4 | 45 | 20-57 |
| Not in MMR | |||||
| < 1 | 32 | 3 | 1 | 35 | 10-70 |
| > 1 | 8 | 1 | 4 | 25 | 12-56 |
Abbreviations: CGCR, cytogenetic complete response; QPCR, quantitative polymerase chain reaction; CML, chronic myelogenous leukemia; MMR, major molecular response.